Liquidia forecasts over $1 billion in 2027 net revenue as YUTREPIA captures nearly 30% of the inhaled prostacyclin market.
Liquidia Corporation (LQDA) targets more than $1 billion in net revenue by 2027, driven by strong adoption of its YUTREPIA therapy. The company reported 5,900 unique patient prescriptions and over 1,100 prescribing physicians as of July 31, Q2 2026.
YUTREPIA now accounts for nearly 30% of the inhaled prostacyclin market, up from minimal share a year earlier. Management highlighted accelerating patient starts, with more than 5,000 patients initiated on therapy.
The revenue projection reflects confidence in continued market penetration and expansion of the therapy’s use in treating pulmonary arterial hypertension.